Payment overview · 2025
General Payments
$358.88
17 reported records · 14 companies
Healthcare provider profile · identity verified
Troy D. Mccurry, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · GAFFNEY, SC · NPI 1255386520
Verified facts
What the public records show
CMS Open Payments records show Troy D. Mccurry, APRN received $358.88 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Qulipta, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.17 | 16.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.80 | 10.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.06 | 8.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.56 | 7.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.86 | 6.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.86 | 6.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.53 | 6.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $21.48 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.21 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.45 | 5.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.43 | 5.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.92 | 5.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.41 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.14 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.88 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 439 | 61 |
| Gabapentin | Gabapentin | 380 | 87 |
| Lisinopril | Lisinopril | 349 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 339 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 238 | 75 |
| Omeprazole | Omeprazole | 231 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 48 |
| Clonazepam | Clonazepam | 176 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 43 |
| Tramadol Hcl | Tramadol Hcl | 157 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 43 |
| Furosemide | Furosemide | 144 | 39 |
| Mirtazapine | Mirtazapine | 138 | 38 |
| Pregabalin | Pregabalin | 135 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 113 | 30 |
| Trazodone Hcl | Trazodone Hcl | 112 | 29 |
| Metformin Hcl | Metformin Hcl | 111 | 42 |
| Losartan Potassium | Losartan Potassium | 110 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 29 |
| Carvedilol | Carvedilol | 95 | 26 |
| Jardiance | Empagliflozin | 93 | 18 |
| Ibuprofen | Ibuprofen | 91 | 25 |
| Ramipril | Ramipril | 89 | 25 |
| Ondansetron Odt | Ondansetron | 86 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 21 |
| Eliquis | Apixaban | 78 | 17 |
| Potassium Chloride | Potassium Chloride | 78 | 29 |
| Meloxicam | Meloxicam | 77 | 28 |
| Lorazepam | Lorazepam | 76 | 18 |
| Glimepiride | Glimepiride | 74 | 20 |
| Alendronate Sodium | Alendronate Sodium | 73 | 21 |
| Famotidine | Famotidine | 73 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 71 | 26 |
| Diazepam | Diazepam | 69 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 67 | suppressed |
| Simvastatin | Simvastatin | 65 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 19 |
| Allopurinol | Allopurinol | 62 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 19 |
| Ezetimibe | Ezetimibe | 59 | 21 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 19 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Ozempic | Semaglutide | 55 | 15 |
| Sertraline Hcl | Sertraline Hcl | 55 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 49 | suppressed |
| Prednisone | Prednisone | 48 | 31 |
| Topiramate | Topiramate | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 15 |
| Spironolactone | Spironolactone | 46 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 39 |
| Promethazine Hcl | Promethazine Hcl | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Baclofen | Baclofen | 37 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 14 |
| Chlorthalidone | Chlorthalidone | 35 | 11 |
| Linzess | Linaclotide | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | 11 |
| Naloxone Hcl | Naloxone Hcl | 26 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | 11 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Febuxostat | Febuxostat | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Topamax | Topiramate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nabumetone | Nabumetone | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Belsomra | Suvorexant | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $358.88 · 17 records | ABBVIE INC. | Auvelity, Dexcom G6 Transmitter, FANAPT, FARXIGA, HETLIOZ, IBSRELA, INGREZZA, JARDIANCE, LINZESS, NURTEC ODT, Ohtuvayre, QULIPTA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error